IRONWOOD PHARMACEUTICALS, INC. Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount
IRONWOOD PHARMACEUTICALS, INC. (IRWD) reported Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount of $20.00 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets
us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount · last filed 2026-02-26
- IRONWOOD PHARMACEUTICALS, INC. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2025 was $20.00M, a 2.91% decline from fiscal 2024.
- IRONWOOD PHARMACEUTICALS, INC. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2024 was $20.60M, a 75.06% decline from fiscal 2023.
- IRONWOOD PHARMACEUTICALS, INC. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2023 was $82.60M.
- IRONWOOD PHARMACEUTICALS, INC. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2022 was -$1.20M.
| Period end | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 12 month |
|---|---|
| 2025-12-31 | $20.00M 10-K · filed 2026-02-26 |
| 2024-12-31 | $20.60M 10-K · filed 2026-02-26 |
| 2023-12-31 | $82.60M 10-K · filed 2025-03-31 |
| 2022-12-31 | -$1.20M 10-K · filed 2024-02-16 |
| 2021-12-31 | -$390.80M 10-K · filed 2023-02-16 |
| 2020-12-31 | -$35.20M 10-K · filed 2023-02-16 |
| 2019-12-31 | -$29.10M 10-K · filed 2021-02-17 |
| 2018-12-31 | $80.70M 10-K · filed 2020-02-13 |
| 2017-12-31 | -$95.80M 10-K · filed 2019-02-25 |
| 2016-12-31 | $66.30M 10-K · filed 2018-02-22 |
| 2015-12-31 | $40.70M 10-K · filed 2017-02-22 |
| 2014-12-31 | $58.70M 10-K · filed 2016-02-19 |
| 2013-12-31 | $105.80M 10-K · filed 2015-02-18 |
| 2012-12-31 | $34.80M 10-K · filed 2014-02-07 |
| 2011-12-31 | $20.30M 10-K · filed 2013-02-21 |
| 2010-12-31 | $16.00M 10-K · filed 2012-02-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |